Last reviewed · How we verify
NCT03760952
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
trial in Refractory Cancer in 242 participants. Completed in 15 November 2022.
15 November 2022
Quick facts
| Lead sponsor | Immatics US, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 242 |
| Start date | 26 February 2019 |
| Primary completion | 15 November 2022 |
| Estimated completion | 15 November 2022 |
| Sites | 4 locations across United States |
Conditions studied
- Refractory Cancer — all drugs for Refractory Cancer →
- Recurrent Cancer — all drugs for Recurrent Cancer →
- Adult Solid Tumor — all drugs for Adult Solid Tumor →
- Neoplasms — all drugs for Neoplasms →
Sponsor
Immatics US, Inc. — full company profile →
Who can join
18 and older, any sex, with Refractory Cancer or Recurrent Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This screening study will identify HLA molecular subtype positive and tumor antigen target(s) positive patients who may be eligible for enrollment into Immatics clinical studies. This screening study is intended for patients with advanced and/or metastatic solid cancers. No treatment intervention will occur as part of this screening study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03760952
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Refractory Cancer
Currently open trials in the same condition.
- NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
- NCT06096038 — Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC · Phase 1, PHASE2 · recruiting
- NCT06184035 — A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer · Phase 1, PHASE2 · recruiting
- NCT05852717 — Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed · Phase 2 · recruiting
- NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting
Other Immatics US, Inc. trials
Trials by the same sponsor.
- NCT03441100 — TCR-engineered T Cells in Solid Tumors: IMA202-101 · Phase 1 · completed
- NCT03247309 — TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) · Phase 1 · completed
- NCT02876510 — ACTolog in Patients With Solid Cancers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03760952 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Immatics US, Inc.
- Last refreshed: 4 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03760952.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing